이 페이지를 로드하는 동안 오류가 발생한 것 같습니다.
지원팀에 전달되었습니다. 만약 문제가 지속될 경우 이메일 지원 위젯을 통해 다시 문의 부탁드립니다.
Trend | Peers | Company |
---|---|---|
Is return on equity increasing? | Yes | No |
Is net profit margin increasing? | Yes | No |
Is asset turnover increasing? | Yes | No |
Is equity multiplier increasing? | Yes | Yes |
Competitors Used |
---|
Eli Lilly and Company |
Jazz Pharmaceuticals plc |
Merck & Co., Inc. |
Teva Pharmaceutical Industries Limited |
Pfizer Inc. |
Return on Equity Benchmarks | ||||||||
Comparable Companies | ||||||||
LLY | JAZZ | MRK | TEVJ.F | PFE | AXSM * | |||
Return On Equity | ||||||||
Latest Twelve Months | 85% | 14% | 41% | -25% | 9% | -232% | ||
Fiscal Year - 1 | 49% | 12% | 1% | -7% | 2% | -159% | ||
Fiscal Year - 2 | 64% | -6% | 34% | -27% | 36% | -299% | ||
Fiscal Year - 3 | 76% | -9% | 39% | 4% | 32% | NA | ||
Fiscal Year - 4 | 150% | 7% | 18% | -33% | 10% | NA | ||
Fiscal Year - 5 | 75% | 18% | 22% | -7% | 17% | NA | ||
Average | 83% | 6% | 26% | -16% | 18% | -230% | ||
Median | 75% | 10% | 28% | -16% | 14% | -232% | ||
Benchmarks | Ticker | |||||||
Eli Lilly and Company | NYSE:LLY | |||||||
Jazz Pharmaceuticals plc | NasdaqGS:JAZZ | |||||||
Merck & Co., Inc. | NYSE:MRK | |||||||
Teva Pharmaceutical Industries Limited | OTCPK:TEVJ.F | |||||||
Pfizer Inc. | NYSE:PFE |
Financial Performance | ||||||||
Comparable Companies | ||||||||
(in millions) | LLY | JAZZ | MRK | TEVJ.F | PFE | AXSM * | ||
Latest Fiscal Year | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
LTM Period | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
Revenues | ||||||||
Latest Twelve Months | 45,043 | 4,069 | 64,168 | 16,544 | 63,627 | 386 | ||
Fiscal Year | 45,043 | 4,069 | 64,168 | 16,544 | 63,627 | 386 | ||
Fiscal Year - 1 | 34,124 | 3,834 | 60,115 | 15,846 | 59,554 | 271 | ||
Fiscal Year - 2 | 28,541 | 3,659 | 59,283 | 14,925 | 101,175 | 50 | ||
Fiscal Year - 3 | 28,318 | 3,094 | 48,704 | 15,878 | 81,288 | NA | ||
Fiscal Year - 4 | 24,540 | 2,364 | 41,518 | 16,659 | 41,651 | NA | ||
Fiscal Year - 5 | 22,320 | 2,162 | 39,121 | 16,887 | 40,905 | NA | ||
Net Income | ||||||||
Latest Twelve Months | 10,590 | 560 | 17,117 | (1,639) | 8,020 | (287) | ||
Fiscal Year | 10,590 | 560 | 17,117 | (1,639) | 8,020 | (287) | ||
Fiscal Year - 1 | 5,240 | 415 | 365 | (559) | 2,134 | (239) | ||
Fiscal Year - 2 | 6,245 | (224) | 14,519 | (2,446) | 31,366 | (187) | ||
Fiscal Year - 3 | 5,582 | (330) | 12,345 | 417 | 22,413 | (130) | ||
Fiscal Year - 4 | 6,194 | 239 | 4,519 | (3,990) | 6,630 | (103) | ||
Fiscal Year - 5 | 4,638 | 523 | 5,690 | (999) | 10,707 | (68) | ||
Total Assets | ||||||||
Latest Fiscal Quarter Prior | 64,006 | 11,393 | 106,675 | 43,479 | 226,501 | 588 | ||
Latest Fiscal Quarter | 78,715 | 12,012 | 117,106 | 39,326 | 213,396 | 568 | ||
Fiscal Year | 78,715 | 12,012 | 117,106 | 39,326 | 213,396 | 568 | ||
Fiscal Year - 1 | 64,006 | 11,393 | 106,675 | 43,479 | 226,501 | 588 | ||
Fiscal Year - 2 | 49,490 | 10,835 | 109,160 | 44,011 | 197,205 | 331 | ||
Fiscal Year - 3 | 48,806 | 12,299 | 105,694 | 47,666 | 181,476 | 88 | ||
Fiscal Year - 4 | 46,633 | 6,536 | 91,588 | 50,640 | 154,229 | 186 | ||
Fiscal Year - 5 | 39,286 | 5,539 | 84,397 | 57,470 | 167,594 | 221 | ||
Fiscal Year - 6 | 43,908 | 5,203 | 82,637 | 60,683 | 159,422 | 15 | ||
Common Equity | ||||||||
Latest Fiscal Quarter Prior | 10,772 | 3,737 | 37,581 | 7,506 | 89,014 | 191 | ||
Latest Fiscal Quarter | 14,192 | 4,094 | 46,313 | 5,373 | 88,203 | 57 | ||
Fiscal Year | 14,192 | 4,094 | 46,313 | 5,373 | 88,203 | 57 | ||
Fiscal Year - 1 | 10,772 | 3,737 | 37,581 | 7,506 | 89,014 | 191 | ||
Fiscal Year - 2 | 10,650 | 3,086 | 45,991 | 7,804 | 95,661 | 110 | ||
Fiscal Year - 3 | 8,979 | 3,965 | 38,184 | 10,278 | 77,201 | 16 | ||
Fiscal Year - 4 | 5,642 | 3,660 | 25,317 | 10,026 | 63,238 | 114 | ||
Fiscal Year - 5 | 2,607 | 3,111 | 25,907 | 13,972 | 63,126 | 179 | ||
Fiscal Year - 6 | 9,829 | 2,757 | 26,701 | 14,707 | 63,388 | 1 |